Earnings per share for the last twelve months: Notable Labs Ltd (NTBL)
Notable Labs, Ltd. (NTBL) faces a liquidity shortage and a dependence on external financing due to high IT development costs. Growth is hindered by complexities in implementing the system within clinics and potential insurance denials. The EPS trend over the last 12 months, where the indicator reaches -1.09, illustrates the dynamics of the company, which created a unique therapy selection method via live-cell testing.
Analytical breakdowns and data insights for company Notable Labs, Ltd. (NTBL)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Debt to Equity Notable Labs, Ltd.|NTBL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Notable Labs Inc.|NTBL - Company Cumulative Indebtedness|Debts to Book Capitalization Notable Labs Ltd|NTBL - Company Long-Term Debts|Company Short-Term Debts Notable Labs|Quick Liquidity notablelabs.com
- net income and valuation multiples indicators:
NTBL - Company Net Income|Projected Future Earnings Notable Labs, Ltd.|NTBL - Market Cap to Earnings|Projected Price to Earnings Notable Labs Inc.|NTBL - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Notable Labs Inc.|NTBL - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Notable Labs|NTBL - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth notablelabs.com|NTBL - Earnings per share growth in current year|Net earnings per share growth forecast for next year Notable Labs, Ltd.
- revenue and sales proceeds data:
Summary company analytics:notablelabs.com (NTBL)
Annual earnings per share measures the portion of actual income attributable to a single security. Growth in this ratio confirms capital management efficiency and the fundamental stability of the business. By analyzing the trend of the rolling annual EPS, an investor determines the degree of overpayment for the asset. For Notable Labs, Ltd. (NTBL), profit dynamics depend directly on the cost of external substance synthesis. The absence of proprietary plants makes this indicator sensitive to the pricing power of outsourcing laboratories.
Competitors of Notable Labs, Ltd. (NTBL)
ONC - Earnings per share for the last twelve months|HALO - Net earnings per share (EPS TTM)|RevMed (RVMD) - Earnings per share for the last twelve months|Ascentage - Earnings per share for the trailing year|CGON (CG Oncology Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma URGN|Net earnings per share (EPS TTM) BCAX|PSNL: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Erasca Corp ERAS|Delcath Corp (DCTH) - Net earnings per one share for the last twelve months|YMAB - Earnings per share for the last twelve months|Earnings per share for the trailing year AURA (Aura Biosciences, Inc.)|CADL: Net earnings per share (EPS TTM)|Accuray Inc (ARAY) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months SELLAS Life Sciences Group|Net earnings per share (EPS TTM) Actuate Therapeutics, Inc.|Earnings per share for the last twelve months citiusonc.com (CTOR)|Net earnings per share (EPS TTM) TuHURA (HURA)|Net earnings per share (EPS TTM) TARA (protaratx.com)|Earnings per share for the trailing year FATE|WHWK - Earnings per share for the last twelve months|Earnings per share for the trailing year TCRX (tscan.com)|Champions Oncology (CSBR) - Earnings per share for the last twelve months|XBiotech Inc - Earnings per share for the trailing year|Earnings per share for the last twelve months cel-sci.com|OS Therapies (OSTX) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|Earnings per share for the last four quarters ARTV|Adlai Nortye Ltd. - Net earnings per share for the last 12 months|Earnings per share for the trailing year VERU|tempesttx.com - Net earnings per share (EPS TTM)|XLO - Net earnings per share (EPS TTM)|Enochian BioSciences (RENB) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Mural Oncology plc (MURA)|Earnings per share for the last twelve months Kairos Pharma Ltd|Net earnings per share (EPS TTM) OnKure Therapeutics|Net earnings per share for the last 12 months GDTC (w2.cytomed.sg)|Net earnings per share (EPS TTM) Curis Inc. (CRIS)|Earnings per share for the last twelve months Apollomics Inc. APLM|Earnings per share for the trailing year THAR|ADVB - Earnings per share for the last twelve months|GNPX - Net earnings per share (EPS TTM)|CLDI (calidibio.com) - Net earnings per share for the last 12 months|SBFM - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months XBIO|Salarius (SLRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Purple Biotech Ltd. (PPBT)|Earnings per share for the last four quarters AONC|Earnings per share for the last twelve months BeiGene BGNE|CKPT - Net earnings per share for the last 12 months|elevationoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ICAD (icadmed.com)|IKNA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months VIRX|MOR (MorphoSys Corporation) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NAYA Biosciences Inc NAYA|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
